Author

L. Janeckova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

D. Hrckulak· 2 shared E. Sloncova· 2 shared J. Svec· 2 shared M. Vojtechova· 2 shared V. Korinek· 2 shared A. M. Garcia· 1 shared C. Pallavicini· 1 shared C. Sanz· 1 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Hrckulak

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

TROP2 represents a negative prognostic factor in colorectal adenocarcinoma and its expression is associated with features of epithelial-mesenchymal transition and invasiveness

J. Svec, M. Stastna, L. Janeckova, D. Hrckulak, M. Vojtechova, J. Onhajzer, V. Kriz, K. Galuskova, E. Sloncova, J. Kubovciak, L. Pfeiferova, J. Hrudka, R. Matej, P. Waldauf, L. Havluj, , V. Korinek

This study shows TROP2 is a negative prognostic factor in colorectal cancer, linked to metastasis and poor differentiation, and suggests it could be a therapeutic target.

bioRxiv · Jul 27, 2022Cancer Biology

Tumor suppressor Hypermethylated in Cancer 1 represses expression of cell cycle regulator E2F7 in human primary cells

L. Lanikova, J. Svec, L. Janeckova, V. Pospichalova, N. Dibus, M. Vojtechova, D. Hrckulak, E. Sloncova, H. Strnad, V. Korinek

This study shows that HIC1 represses E2F7, leading to altered cell cycle progression and DNA repair in CRC, with E2F7 levels linked to patient prognosis.

bioRxiv · Jul 25, 2022 · PreprintCancer Biology

Natural language signatures of psilocybin microdosing

C. Sanz, F. Cavanna, S. Muller, L. A. de la Fuente, F. Zamberlan, M. Palmucci, L. Janeckova, M. Kuchar, F. Carrillo, A. M. Garcia, C. Pallavicini, E. Tagliazucchi

This study uses natural language analysis to detect psilocybin microdosing effects, finding significant differences in speech metrics between active and placebo conditions.

bioRxiv · Feb 20, 2022Pharmacology & Toxicology